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Plasmacytoid dendritic cells (pDCs) at tumor sites are often tolerogenic. Although pDCs initiate innate and
adaptive immunity upon Toll-like receptor (TLR) triggering by pathogens, TLR-independent signals may be
responsible for pDC activation and immune suppression in the tumor inflammatory environment. To identify
molecules that are potentially involved in alternative pDC activation, we explored the expression and function of
lymphocyte activation gene 3 (LAG-3) in human pDCs. In this report, we showed the expression of LAG-3 on the
cell surface of a subset of circulating human pDCs. LAG-3þ pDCs exhibited a partially mature phenotype and
were enriched at tumor sites in samples from melanoma patients. We found that LAG-3 interacted with major
histocompatibility complex class II (MHC-II) to induce TLR-independent activation of pDCs with limited IFNa and
enhanced IL-6 production. This in vitro cytokine profile of LAG-3-activated pDCs paralleled that of tumor-
associated pDCs analyzed ex vivo. By confocal microscopy, LAG-3þ pDCs detected in melanoma-invaded lymph
nodes (LNs) stained positive for IL-6 and preferentially localized near melanoma cells. These results suggest that
LAG-3-mediated activation of pDCs takes place in vivo at tumor sites, and it is in part responsible for directing an
immune-suppressive environment.
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INTRODUCTION
Following Toll-like receptor (TLR) stimulation, human plas-
macytoid dendritic cells (pDCs) mediate antiviral activity and
promote innate and adaptive protective immunity through the
massive release of IFNa (Cella et al., 1999; Siegal et al., 1999;
Kadowaki et al., 2000). Both mouse and human pDCs also
possess tumor necrosis factor–related apoptosis-inducing
ligand (TRAIL)– or granzyme B–mediated cytotoxic functions
(Matsui et al., 2009; Jahrsdorfer et al., 2010; Drobits et al.,
2012). pDCs are directly involved in central and peripheral
tolerance and upon selective stimuli can induce the genera-
tion and expansion of regulatory T cells (Tregs) (Swiecki and
Colonna, 2010; Faget et al., 2012; Hadeiba et al., 2012).
Along with these pleiotropic functions, pDCs exhibit a com-
plex cell surface phenotype, and several subsets of pDCs
with discrete cell surface markers are potentially involved
in mediating pDC-specific functions (Matsui et al., 2009;
Hadeiba et al., 2012; Maazi et al., 2013). Upon TLR trigger-
ing, IFNa is produced at far higher levels than other inflamma-
tory cytokines, including IL-6, and activated pDCs initiate a
complex signaling network that is responsible for the recruit-
ment and activation of different immune cells (Piqueras et al.,
2006; Decalf et al., 2007).
The pDCs that are recruited to the tumor site, including
melanoma (Gerlini et al., 2007, 2010; Vermi et al., 2011),
commonly display tolerogenic activities and are often
associated with poor clinical outcomes in several types of
cancer (Treilleux et al., 2004; Jensen et al., 2012; Demoulin
et al., 2013). Although it is known that pDCs sense pathogens
through TLRs, and TLR-dependent activation has a role in
several autoimmune settings (Barrat et al., 2005; Nestle et al.,
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2005), there is no clear evidence for TLR-dependent activation
of pDCs in cancer. Damage-associated molecular patterns, the
endogenous TLR ligands potentially present at tumor sites,
suppress rather than activate the pDCs (Popovic et al., 2006).
This scenario leaves open the possibility that, in a complex
inflammatory environment, other TLR-independent signals/
receptors have a prominent role in the activation of pDCs,
and that these alternative pathways of activation can skew
pDCs toward suppressive rather than protective immune
functions. Consistent with this hypothesis, we have pre-
viously shown that upon CD91–gp96 interactions, pDCs
release inflammatory cytokines but maintain an immature
phenotype (De Filippo et al., 2008).
To identify other cell surface receptors potentially involved
in pDC activation in a pathogen-free setting, we explored the
expression pattern and function of lymphocyte activation
gene-3 (LAG-3, CD223). LAG-3 is a CD4 homolog, and it
binds to major histocompatibility complex class II (MHC-II)
molecules. LAG-3 has key roles in T-cell homeostasis, and it
has been associated with regulatory functions (Grosso et al.,
2007; Blackburn et al., 2009; Camisaschi et al., 2010;
Gagliani et al., 2013). Soluble LAG-3 (Triebel, 2003) regu-
lates the differentiation and activation of monocyte-derived
DCs (Casati et al., 2006). Moreover, LAG-3 is uniformly
expressed on the surface of mouse pDCs, and it contributes
to their homeostatic regulation (Workman et al., 2009).
In our study, we extended the above observation to an
examination of human pDCs. However, in contrast to pDCs
in mice, we found that not all human pDCs homogenously
expressed LAG-3. Instead, LAG-3 comprised a subset of
pDCs with a partially mature phenotype enriched at tumor
sites. Our data showed that LAG-3 was functional, and it
mediated TLR-independent activation of pDCs in the setting
of a proinflammatory, immune-suppressive environment at
a tumor site.
RESULTS
LAG-3 identifies a subpopulation of human pDCs enriched
in tumor-invaded LNs and displaying a partially activated
phenotype
LAG-3 is a CD4-related protein that possesses regulatory
activities. Because pDCs may have immunosuppressive func-
tions and are CD4 positive, we explored the expression of
LAG-3 on these cells. The analysis of human pDCs from
healthy donor (HD) peripheral blood mononuclear cells
(PBMCs) that were identified as CD123, BDCA-2 double-posi-
tive cells or were purified by immunomagnetic bead sorting
showed a discrete subpopulation of LAG-3þ cells (Figure 1a
and b). The percentage of LAG-3þ pDCs was identical when
PBMCs or isolated pDCs were assessed (mean±SD: pDCs
from PBMCs: 6.02±5.9; isolated pDCs: 6.01±5.2; Figure 1c).
After 24 hours of in vitro stimulation with IL-3 and CpG, the
percentage of LAG-3þ cells increased in purified pDCs as
compared with stimulation with IL-3 alone (mean±SD: IL-3:
3.53±5.20; CpG: 13.15±7.89, Figure 1d), consistent with the
notion that LAG-3 is a marker of activation for immune cells.
No significant differences were observed in the percentage
of LAG-3þ pDCs between HD and melanoma patient (MP)
PBMCs, although HD cells displayed a slightly increased
frequency of LAG-3þ pDCs (mean±SD: HD: 6.02±5.9;
MP: 3.5±2.7, Figure 2a). Conversely, pDCs detected in
melanoma-invaded lymph nodes (LNs) and in melanoma
cutaneous metastasis (MA-pDCs) were strongly enriched for
LAG-3þ cells (mean±SD: LN-pDC: 54.3±15.5; CUT-pDC:
42.7±7.7, Figure 2a).
Because LAG-3 was upregulated in pDCs upon in vitro
activation (Figure 1d), we characterized the activation and
maturation status of pDCs in conjunction with analysis of
LAG-3 expression. pDCs from HD and MP PBMCs displayed a
similar activation status characterized by high levels of CD86
and TRAIL. MA-pDCs showed a higher percentage of cells that
were CD80, CD83 and TRAIL positive (mean±SD: MA-pDC:
CD80, 15.84±8.55; CD83, 38.74±27.69; TRAIL, 64.56±
27.11; Figure 2b and Supplementary Figure S1a, b, d online).
Surprisingly, CD86 was not notably expressed on MA-pDCs
(mean±SD: MA-pDC: CD86, 21.75±8.9; Figure 2b and
Supplementary Figure S1c online), possibly suggestive of a
more tolerogenic phenotype (Sansom et al., 2003; Zheng
et al., 2004).
CD80-, CD83-, CD86-, and TRAIL-positive pDCs were
significantly enriched in the LAG-3þ pDC subset of the MP
or HD PBMCs as well as the MA-pDCs (Figure 2c–e and
Supplementary Figure S2 online). This analysis indicates
that LAG-3 is preferentially expressed by partially activated
pDCs in vivo.
LAG-3þ pDCs migrate toward tumors
Considering the enrichment of LAG-3þ cells in MA-pDCs,
we analyzed the migration properties of the cells. In chemo-
taxis assays, purified pDCs migrated in response to the positive
control CCL5 (chemokine (C-C motif) ligand 5) (Sozzani et al.,
2010), but the supernatants (SNs) conditioned by the Me 204
and LM65 melanoma cell lines showed the strongest
chemoattractive properties (Figure 3a). Migrated and non-
migrated pDCs were analyzed for LAG-3 expression. Unlike
the nonspecific migration observed in normal medium, although
with no statistical significance, the melanoma conditioned
SNs and CCL5 displayed a trend in attracting LAG-3þ pDCs
(Figure 3b).
LAG-3/MHC-II interaction induces TLR-independent activation
of pDCs in vitro
LAG-3 is triggered by binding to MHC-II (Huard et al., 1997).
To explore the MHC-II-mediated engagement of LAG-3 on
pDCs, COS-7 cells expressing HLA-DR-1*0402 (COS-7 DRþ )
and COS-7 cells containing the empty vector (COS-7 DR-null)
were used as stimulators and negative controls, respectively.
Purified pDCs cocultured in vitro with the COS-7 DRþ cells
produced IFNa and IL-6 (Figure 4a and b). pDC/COS-7
DRþ cocultures incubated in the presence of anti-HLA-DR
or anti-LAG-3 antibodies showed a significant reduction in
cytokine release, thereby proving the direct involvement of
LAG-3 and MHC-II molecules in pDC activation (Figure 4a
and b).
The relative levels of IFNa and IL-6 that were induced by
LAG-3 were compared with those induced by TLR-mediated
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pDC activation. LAG-3 activation on pDCs mediated by the
COS-7 DRþ cell coculture was less efficient at inducing IFNa
than was the TLR-mediated activation (Figure 4c). Conversely,
the COS-7 DRþ cell–induced activation of LAG-3 on pDCs
resulted in a consistently higher level of IL-6 production than
that obtained with CpG stimulation (Figure 4c and d). TLR
stimulation produced an average of 305±49 (mean±SD)
molecules of IFNa for each molecule of IL-6, whereas
LAG-3 activation yielded only an average of 2.99±0.7993
(mean±SD) molecules (Figure 4e). Thus, the imbalance in
cytokine production resulted in a milieu skewed to IFNa in
TLR-activated pDCs or IL-6 in LAG-3-activated pDCs.
COS-7 DRþ or COS-7 DR-null–activated pDCs were
used to stimulate allogeneic CD4þCD25 T cells. After
4 days of in vitro stimulation, cells were collected and Treg
frequency monitored by FACS. CD3þ Foxp3þ IL-10þ Tregs
were induced by pDCs preactivated by COS-7 DRþ but
not by COS-7 DR-null cells (Figure 4f and Supplementary
Figure S3 online).
The same set of experiments performed with COS-7 cells
were performed using HLA-DRþ melanoma cells, and these
studies confirmed that melanoma HLA-DRþ cells were able
to activate pDCs, and that the activation involved LAG-3 and
HLA-DR (Figure 4g and h). Similar to the results using COS-7
DRþ cells, melanoma-mediated activation of pDCs resulted
in unbalanced cytokine production characterized by impaired
IFNa and enhanced IL-6 release (Figure 4i–k).
To verify that this differential cytokine profile could also
occur in vivo in MA-pDCs, we compared the intracellular
production of IL-6 and IFNa ex vivo in MA-pDCs identified
as LIN CD123high CD11c DRþ . As shown in Figure 4l,
MA-pDCs displayed an enhanced production of IL-6 com-
pared with IFNa at the tumor site, evaluated by intracellular
FACS analysis as percentage of cytokine-positive pDCs
(mean±SD: % of IL-6þ cells: 33.6±26.6; % of IFNa-positive
cells: 15.3±16.7; P¼ 0.0143), supporting the hypothesis that
alternative LAG-3-mediated activation of pDCs could also
occur in vivo.
At the tumor site, LAG-3þ pDCs preferentially localize in the
proximity of melanoma cells and produce IL-6
To gain further insights into pDC presence at the tumor site,
immunohistochemical staining and confocal analyses were per-
formed on paraffin-embedded sections of melanoma-invaded
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Figure 1. The lymphocyte activation gene 3 (LAG-3) defines a discrete subpopulation of human plasmacytoid dendritic cells (pDCs). The pDCs, identified
in healthy donor (HD) peripheral blood mononuclear cells (PBMCs) by multiparametric FACS analysis as BDCA-2þ CD123high according to the gating
strategy reported in (a), or isolated as untouched cells by immunomagnetic bead sorting and checked for purity by assessing blood dendritic cell antigen 2
(BDCA-2) expression (b), were analyzed for the expression of LAG-3. FSC, forward scatter; SSC, side scatter. (c) The frequency of LAG-3þ pDCs evaluated
in pDCs gated in PBMCs (n¼ 17) or in purified pDCs (n¼9) is reported. Purified pDCs cultured with IL-3 or IL-3 plus CpG for 24 hours at 37 1C were analyzed
for the expression of the maturation/activation markers CD80, CD83, and LAG-3. (d) The mean percentages with error bars of cells expressing these
markers (n¼ 5).
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LNs using antibodies specific for BDCA-2, LAG-3, IL-6,
MART-1, and HLA-DR.
The BDCA-2 staining confirmed the FACS data and
revealed the presence of numerous pDCs at the tumor site
(Supplementary Figure S4 online). Interestingly, BDCA-2þ
cells preferentially accumulated around and inside the tumor
tissue with a pattern suggestive of migratory flux (Figure 5a,
left panels). The IL-6 staining of consecutive sections high-
lighted the presence of cells displaying distinct pDC morpho-
logy, and these pDCs were positive for IL-6 and located in the
same area as the BDCA-2þ cells (Figure 5a, right panels).
Similar to the FACS data shown in Figure 1, the confocal
analysis evidenced the presence of double-positive BDCA-2/
LAG-3 cells (Figure 5b and d–f; mean±SD: % of BDCA-2/
LAG-3 among BDCA-2 cells: 52.6±9.9; Supplementary Table
S1 online). By three-color staining and confocal analysis,
BDCA-2/LAG-3-positive pDCs were shown to produce
IL-6 (Figure 5b, d and e; mean±SD: % of BDCA-2/LAG-3/
IL-6 among BDCA-2 cells: 71.7±15.4; Supplementary Table
S1 online), to localize to the tumor area (Figure 5c and d), and
to maintain direct contact with MART-1þ melanoma cells
(Figure 5f). Metastatic melanoma cells are known to be hetero-
geneous for the expression of the HLA-DR molecules in vivo
(van Vreeswijk et al., 1988), and here approximately one out
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Figure 2. The lymphocyte activation gene 3-positive (LAG-3þ ) plasmacytoid dendritic cells (pDCs) are enriched in melanoma-associated pDCs (MA-pDCs)
and display a partially activated phenotype. pDCs were identified by multiparametric FACS analysis as described for Figure 1 in the peripheral blood mononuclear
cells (PBMCs) of healthy donors (PBMC DON), stage III and IV melanoma patient (PBMC PT), and melanoma-invaded lymph nodes (LN) and cutaneous
metastasis (CUT) (MA-pDC). The gated pDCs were then analyzed for the expression of (a) LAG-3, and (b) CD80, CD83, CD86, and tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL). pDCs from (c) healthy donor PBMCs (PBMC DON pDC), (d) melanoma patient PBMCs (PBMC PT pDC), and (e) melanoma-
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of three melanoma cells displayed positivity for this marker
(Figure 5g). Moreover, Foxp3 and CD163 staining of con-
secutive sections showed an enrichment in Tregs and macro-
phages inside and in the proximity of the tumor, where pDCs
were also located (Supplementary Figures S5 and S6 online).
These results suggest that LAG-3-mediated activation of pDCs
may occur in vivo at the tumor site and could contribute to
the generation/maintenance of an IL-6-driven, inflammatory,
immune-suppressed tumor microenvironment.
Alternatively activated pDCs induce monocytes to release CCL2
To dissect the possible paracrine role of the imbalance in
cytokines produced upon LAG-3-mediated pDC activation,
monocytes purified from HD PBMCs were exposed to SNs
conditioned by pDCs cocultured with HLA-DRþ melanoma
cells. The pDC-conditioned medium induced monocytes to
produce CCL2 (chemokine (C-C motif) ligand 2), a chemokine
known to mediate immunosuppression and recruit inflam-
matory cells to the tumor site (Figure 6). CCL2 production
was strongly inhibited by a neutralizing anti-IL-6 antibody
(Figure 6), thus supporting the primary role of pDC-derived
IL-6 in the local production of CCL2.
DISCUSSION
The pDCs exhibit a complex surface phenotype that reflects
their pleiotropic functions (Maazi et al., 2013). This study
demonstrated the expression and functional role of LAG-3 on
a subset of human pDCs. The engagement of LAG-3 with its
nominal ligand, MHC-II, led to the functional activation of
pDCs that mirrored the features of immunosuppressive pDCs.
Among circulating pDCs, LAG-3þ pDCs represented a
discrete population with a partially activated phenotype that
were present at a similar frequency in the PBMCs of HDs and
in the PBMCs of stage III and IV MPs. LAG-3þ pDCs in MPs
preferentially accumulated in tumor-invaded LNs. Tumor-
derived factors potentially involved in such recruitment are
still to be fully elucidated. However, it is known that SDF-1/
CXCL12 and CCL20, both expressed by peritumoral stromal
cells and/or melanoma cells, may indeed have an active role
(Charles et al., 2010; Demoulin et al., 2013).
Using two independent in vitro systems, namely the COS-7
DRþ cell line and the HLA-DRþ melanoma cell line, we
showed that the LAG-3/MHC-II interaction mediated a TLR-
independent activation of pDCs characterized by enhanced
IL-6 and limited IFNa production. This peculiar cytokine
profile was also demonstrated ex vivo in MA-pDCs. More-
over, by confocal microscopy of melanoma-invaded LNs, we
confirmed that LAG-3þ pDCs maintained tight contact with
melanoma cells and actively produced IL-6. These findings
strongly support the view that in vivo the LAG-3/MHC-II
interaction activated pDCs. Melanocytes acquire MHC-II
expression following transformation (Guerry et al., 1987;
Ruiter et al., 1991), and MHC-II expression increases in
melanoma with the grade of malignancy and lesion
thickness (Brocker et al., 1984; Becker et al., 1993) and is
associated with an unfavorable prognosis (van Duinen et al.,
1988; Ruiter et al., 1991). Thus, the MHC-II/LAG-3 interaction
and the resulting pDC activation are likely exacerbated during
tumor progression.
IFNa is a key cytokine that supports pDC-driven protective
immune responses (Cella et al., 1999; Siegal et al., 1999;
Kadowaki et al., 2000). Conversely, a common trait of the
tumor-associated, immunosuppressive pDCs is their limited
capacity to release IFNa (Hartmann et al., 2003; Vermi et al.,
2003; Gerlini et al., 2007; Labidi-Galy et al., 2011; Sisirak
et al. 2012). The pDC subsets express different cell surface
receptors that, once triggered by ligands at the tumor site,
suppress TLR-induced IFNa in the cells and thus act as physio-
logical regulators of the tolerogenic/activating functions of
pDCs (Grage-Griebenow et al., 2007; Shin et al., 2008;
Tsukamoto et al., 2009; Fabricius et al., 2010). Our study
shows the in vitro and likely in vivo existence of an alternative
pathway of pDC activation that does not involve TLRs or its
functional modulation by the tumor microenvironment. It is
possible that the tumor itself or other inflammatory HLA-DRþ
cells present at the tumor site directly trigger an alternative,
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immunosuppressive, IFNa-deficient activation of pDCs. The
LAG-3 cell surface molecules expressed by pDCs and engaged
by MHC-II have a key role in this activation pathway.
The pDCs impaired in IFNa production exert their suppres-
sive activities mainly by favoring the generation of Tregs
(Swiecki and Colonna, 2010; Faget et al., 2012; Hadeiba
et al., 2012). Here, we showed that low IFNa and enhanced
IL-6 production were key features of LAG-3-mediated alter-
native pDC activation, and that LAG-3-activated pDCs promo-
ted in vitro the generation of Tregs from allogenic CD4þ
CD25 T cells. The proinflammatory and immunosuppres-
sive activities of IL-6 via signal transducer and activator of
transcription-3 (STAT3) signaling are well known (Yu et al.,
2009). Here, we found that the medium conditioned by
alternatively activated pDCs induced monocytes to produce
CCL2, and this production was in part IL-6 dependent as has
been previously shown (Roca et al., 2009). CCL2 is crucial for
the recruitment of myeloid-derived suppressor cells at the
tumor site and for M2 macrophage polarization (Huang et al.,
2007; Roca et al., 2009). Our data indeed showed a selective
accumulation of macrophages expressing the CD163 marker
in the proximity of and inside the tumor nest, where
macrophages were tightly intermingled with melanoma cells
(Supplementary Figure S6 online). Moreover, CCL2 might
have direct clinical relevance in modulating the response
to BRAF inhibitors as demonstrated in a mouse model of
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Figure 4. Lymphocyte activation gene 3 (LAG-3) triggering induces plasmacytoid dendritic cell (pDC) activation. Healthy donor (HD) pDCs were cultured
in complete medium (Med) alone or added with the stimulating agents indicated in each histogram (a–c and g–i; Mel, HLA-DRþ melanoma cell line LM65).
(d, j) The ratio between the quantity of IL-6 produced by pDCs stimulated as indicated in the y axis (n¼ 5); (e, k) the ratios between IFNa and IL-6 produced
by pDCs stimulated as indicated (n¼ 5). (f) The percentages of regulatory T cells (Tregs; Foxp3þ IL-10þ in gated CD3) induced in CD4þCD25 T cells
cultured with the indicated stimuli (n¼ 2). (l) The ex vivo percentages of IL-6þ and IFNaþ pDCs in melanoma-invaded lymph node (LNs; black dots)
and in cutaneous metastasis (red dots). The P-value was calculated using paired t-tests.
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melanoma (Knight et al., 2013). Thus, the cytokine profile
demonstrated ex vivo in MA-pDCs and the ability of pDCs
activated in vitro by LAG-3 to skew T-cell differentiation
toward Treg phenotype are indicative of a tolerogenic,
immunosuppressive role. This conclusion potentially contrasts
with the cell surface phenotype of MA-pDCs that demon-
strated positivity for CD80 and CD83 expression. However, it
should be noted that compared with PBMC–pDCs, MA-pDCs
had a lower frequency of CD86þ cells (Figure 2b and
Supplementary Figure S1c online), possibly suggesting a more
BDCA-2 IL-6 BDCA-2 LAG-3 IL-6 MERGE
BDCA-2 LAG-3
BDCA-2 LAG-3 MART1 Merge MERGEHLA-DR MART1
IL-6 MERGE
Figure 5. Lymphocyte activation gene 3-positive (LAG-3þ ) plasmacytoid dendritic cells (pDCs) localized at tumor site are positive for IL-6. Consecutive
sections of melanoma-invaded lymph nodes (LNs) were stained with anti-BDCA-2 antibody (Ab) to identify pDCs (a, left column) and anti-IL-6 Ab
(a, right column); arrows indicate the presence of BDCA-2þ and IL-6þ cells, respectively. Scale bar¼ 200mm. (b, d, e) Confocal analysis of the blood dendritic
cell antigen 2 (BDCA-2; green), LAG-3 (blue), and IL-6 (red) molecules shows the presence of triple-positive cells. (c) By immunohistochemistry (IHC),
a pDC positive for the expression of BDCA-2 is evidenced in the proximity of the tumor area (scale bar¼ 50mm). Consecutive sections were also stained with
anti-MART-1 (red) and anti-HLA-DR (green) Abs. LAG-3þBDCA-2þ pDCs, in direct contact with MART-1þ melanoma cells, and MART-1þHLA-DRþ cells
are reported in (f) and (g), respectively.
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Figure 6. Monocytes (Mos) are induced to produce CCL2 (chemokine (C-C motif) ligand 2) by the supernatants (SNs) of plasmacytoid dendritic cells
(pDCs) activated by melanoma cells. Monocytes purified from healthy donor (HD) peripheral blood mononuclear cells (PBMCs) were incubated for 48 hours at
37 1C in pDC-conditioned medium consisting of the SNs of overnight cocultures of purified immature pDCs plus IL-3 or purified pDCs and HLA-DRþ melanoma
cells plus IL-3 in the presence or absence of a blocking anti-IL-6 mAb. Mel, HLA-DRþ melanoma cell line LM65. As a control, the monocytes were
incubated with a medium conditioned overnight with IL-3 and melanoma cells. CCL2 expression was evaluated in monocytes by intracellular staining and
FACS analysis. The percentage of monocytes competent for CCL2 release is indicated in each dot plot.
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tolerogenic phenotype (Sansom et al., 2003; Zheng et al.,
2004). In addition, MA-pDCs were positive for TRAIL and
granzyme B (data not shown) and thus are well equipped for
cytotoxic activities. However, granzyme B–competent pDCs
are impaired in their capacity to induce T-cell expansion
(Jahrsdorfer et al., 2010; Karrich et al., 2013), whereas
melanoma cells exhibit differential sensitivity to TRAIL-
mediated apoptosis (Kurbanov et al., 2007). Moreover, the
LAG-3/MHC-II interaction on melanoma cells may further
enhance their resistance to apoptosis (Supplementary
Figure S6 online) (Hemon et al., 2011).
In conclusion, our data shed light on the phenotypic
heterogeneity of human pDCs and provide evidence of a
new TLR-independent activation of pDCs. This alternative
activation may be partly responsible for establishing an
immune-suppressed environment at the tumor site. However,
the in vitro exposure to CpG fully restored the capacity of
MA-pDCs to produce IFNa (data not shown), thus suggesting
that the detrimental functions of pDCs in the tumor context
can be reverted by therapeutic strategies aimed at restoring
IFNa. Intratumoral administration of TLR ligands potentially
reverts this pDC dysfunctional phenotype, subverts tumor-
induced immunosuppression, and may display curative
effects, as recently reported in preclinical model (Le Mercier
et al., 2013). Moreover, intranodal injections of fully ex vivo–
activated pDCs can be resistant to tumor-induced dysfunction
and be efficient in vaccination approach for melanoma
patients (Tel et al., 2013).
MATERIALS AND METHODS
Cell lines
The HLA-DRþ melanoma cell lines (Me 15392, Me 204, and LM65)
were generated from metastatic melanoma lesions and cultured in
RPMI-1640 supplemented with 10% fetal calf serum. The COS-7 cell
line stably expressing the HLA-DR-1*0402 molecule (COS-7 DRþ )
and the corresponding cells containing the empty construct (COS-7
DR-null) were obtained as previously described (Maccalli et al.,
2003).
Isolation of pDCs and monocytes
PBMCs were isolated as previously described (Casati et al., 2003)
from blood collected from HDs or MPs (stages III–IV). Declaration of
Helsinki Principles was followed and patients gave their written,
informed consent. Single-cell suspensions were obtained by mecha-
nical dissociation or enzymatic digestion of melanoma-invaded
LNs and cutaneous metastasis.
The pDCs and monocytes were isolated from HD PBMCs as
untouched cells by immunomagnetic bead sorting (pDC or monocyte
isolation kits; Miltenyi Biotec, Bergish Gladbach, Germany). A purity
of 96–98% was routinely obtained.
Functional maturation of pDCs and monocytes
Freshly purified pDCs (1 105 cells per well) were cultured for
24 hours at 37 1C in complete medium (10% fetal calf serum/RPMI-
1640, 10 ng ml 1 IL-3) supplemented or not with CpG ODN10103
(1.5mg ml 1; Coley Pharmaceutical Group, Langenfeld, Germany) or
CpG ODN2216 (1.5mg ml
 1; InvivoGen, San Diego, CA). pDCs in
complete medium were cocultured in a ratio of 3:1 with the COS-7
DR-null, COS-7 DRþ , or DRþ melanoma cell lines (LM65,
Me 15392). In the blocking experiments, the cells were preincubated
for 1 hour at 37 1C in complete medium with the following mAbs:
anti-LAG-3 (17B4, Immutep, Chatenay Malabry, France), mouse IgG1
(BD Biosciences, Franklin Lakes, NJ), or anti-human HLA-DR (L243,
Biolegend, San Diego, CA). SNs were collected and stored at
 20 1C, and cells were analyzed by FACS. The SNs were used to
culture monocytes (2 105 cells per well in 96-well flat-bottom
plates) for 48 hours at 37 1C. Anti-human IL-6 (R&D, Minneapolis,
MN) was used.
FACS analysis and cytokine quantification
FACS analyses were performed on PBMCs and MA-derived cells
with a LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Invitrogen,
Carlsbad, CA). After pretreatment with an FcR blocking reagent
(Miltenyi Biotech), cells were stained with the mAbs described in
the table reported in Supplementary Materials and Methods online. In
the SNs, cytokines were measured using the FlowCytomix Multiple
Analyte Detection System (eBioscience, San Diego, CA). Data
acquisition was performed using a Gallios flow cytometer (Beckman
Coulter, Brea, CA), data analysis was performed with FlowJo
Cytometry Analysis (Tree Star, Ashland, OR) or Kaluza (Beckman
Coulter) software, and cytokines were quantified using Pro 2.4
FlowCytomix software (eBioscience).
Chemotaxis assay
Cell migration was evaluated by using cell migration chamber plates
(HTS-transwells, 96 wells, 5.0-mm pores; Corning, Corning, NY).
The migratory conditions are reported in Supplementary Materials
and Methods online.
Isolation and stimulation of CD4þCD25 T cells
COS-7 DRþ and COS-7 DR-null–activated pDCs (see above)
were used to stimulate allogenic CD4þCD25 T cells (pDC/
CD25 ratio 2:1) purified as previously described (Camisaschi et al.,
2010). After 4 days of stimulation, cells were collected and ana-
lyzed by FACS analysis with FITC-conjugated anti-CD3 (BD
Biosciences), allophycocyanin-conjugate anti-Foxp3 (eBioscience),
and phycoerythrin-conjugated anti-IL-10 (BD Biosciences).
Immunohistochemistry and confocal microscopy analysis
Deparaffinized tissue sections were stained with an anti-human
BDCA-2 antibody, clone 104C12.08 (1:50 dilution; Dendritics, Lyon,
France) and an anti-human IL-6 antibody, clone 10C12 (1:50 dilution;
Novocastra, Newcastle, UK). For confocal microscopy, the slides
were treated with the aforementioned mAbs (1:5 dilution) or with the
anti-human MART-1, clone M27C10/9E (1:5 dilution; Novocastra),
anti-human LAG-3 (1:4 dilution; Sigma, St Louis, MO), or HLA-DR
antibody, clone LN3 (1:40 dilution; Thermo Scientific, Waltham,
MA). Additional details are provided in Supplementary Materials and
Methods online.
Statistics
Independent or paired sample t-tests (confidence interval 95%)
were used as indicated in the figure legends. The statistical calcu-
lations were performed using Prism5 software (GraphPad Software,
La Jolla, CA). A P-value of p0.05 was considered statistically
significant.
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